Crossroad between Obesity and Cancer: A Defective Signaling Function of Heavily Lipid-Laden Adipocytes

Zsuzsanna Suba
  • May 2019, InTech
  • DOI: 10.5772/intechopen.85995

Obesity, insulin resistance and cancer are induced by defective estrogen signaling.

What is it about?

All well-known cancer risk factors are in correlation with defects of estrogen signaling in partnership with glucose intolerance as estrogen regulates all steps of glucose uptake. In central obesity, increased secretions of cytokines and growth factors are not causal factors of developing insulin resistance, and unrestrained cell proliferation, but rather, they are compensatory processes so as to increase estrogen synthesis and ER transactivation.

Why is it important?

Understanding the pivotal regulatory roles of healthy abdominal fatty tissue in signal transduction may appropriately answer the question: how can abundant visceral fat deposition lead to serious, life-threatening diseases, such as cardiovascular lesions and malignancies in different organs?

Perspectives

professor Zsuzsanna Suba
National Institute of Oncology Budapest

In obese patients, the causal therapy is the improvement of estrogen signaling in both men and women via estrogen substitution, changes in lifestyle, or use of natural products upregulating the genomic machinery.

Read Publication

http://dx.doi.org/10.5772/intechopen.85995

The following have contributed to this page: professor Zsuzsanna Suba